Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome
Status
Conditions
Details and patient eligibility
About
In a recent multicenter randomized controlled trial, prolonged administration of low-dose methylprednisolone (1mg/kg/day) initiated in early acute respiratory distress syndrome was associated with earlier resolution of pulmonary and extrapulmonary organ dysfunction and reduction in duration of mechanical ventilation and intensive care unit stay. However, glucocorticoids may induce serious adverse events and these adverse events might compensate the positive effect of prolonged methylprednisolone infusion and discourage physicians from treating acute respiratory distress syndrome patients with glucocorticoids. Early prediction of responsiveness to prolonged methylprednisolone infusion would be help to decide whether to continue or not prolonged methylprednisolone infusion and this could reduce the drug related adverse events. We project to evaluate the predictors of responsiveness to prolonged methylprednisolone infusion in early acute respiratory distress syndrome .
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- AECC definition of acute respiratory distress syndrome
- Early acute respiratory distress syndrome (within 72 h of diagnosis)
- PF ratio < 200 at PEEP ≥ 8 cmH2O
Exclusion criteria
- Imminent death
- Contraindication to corticosteroid treatment
- Already on more than 0.5 mg/kg of methylprednisolone or its equivalent
- Evidence of uncontrolled infection
- Refusal of managing physician to participate in the study
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal